Skip to Content

College of Pharmacy


Faculty and Staff

Jing Fang

Title: Assistant Professor / Drug Discovery and Biomedical Sciences
College of Pharmacy
E-mail: fang8@cop.sc.edu
Phone: 803-777-2344
profile

Background

Bachelor of Clinical Medicine
Taishan Medical University, 1998

Master of Immunology
Shandong Academy of Medical Sciences, 2001

Doctor of Genetics
Shanghai Second Medical University, 2004

Postdoctoral Fellowship,
Hematopoiesis and hematologic malignancies
Maine Medical Center Research Institute, 2009                                                                                          

Cincinnati Children’s Hospital Medical Center, 2016

Research Interests

Hematopoiesis is a highly hierarchical process that multipotential hematopoietic stem cells (HSCs) give rise to all the mature blood cells. My research is to understand the molecular mechanisms governing hematopoiesis with animal models, and how dysregulated signaling pathways in HSC may drive hematological malignancies with a focus on myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). My laboratory is currently studying on two molecules, an adaptor protein sequestosome 1 (also known as p62) and a G protein-coupled receptor GPR68, and their functions in hematopoiesis, HSC function and leukemogenesis. Our long-term goal is to uncover novel mechanisms driving malignant hematopoiesis and identify novel therapeutic targets of hematological malignancies.

Selected Publications

  1. Fang J, Muto T, Kleppe M, Bolanos LC, Hueneman KM, Walker CS, Sampson L, Wellendorf AM, Chetal K, Choi K, Salomonis N, Choi Y, Zheng Y, Cancelas JA, Levine RL, Starczynowski DT. Cell Reports, 2018 Jan 30;22(5):1250-1262. PMID: 29386112
  2. Fang J, Bolanos L, Choi K, Liu X, Christie S, Akunuru S, Kumar R, Wang D, Chen X, Greis K, Stoilov P, Filippi M, Maciejewski J, Garcia-Manero G, Weirauch M, Salamonis N, Geiger H, Zheng Y, Starczynowski D. Ubiquitination of a spliceosome auxiliary factor by TRAF6 links chronic innate immune signaling with hematopoietic defects and myelodysplasia. Nature Immunology, 2017 Mar 22;18(4):474. PMID: 28024152
  3. Fang J, Liu X, Bolanos L, Barker B, Rigolino C, Cortelezzi A, Oliva EN, Cuzzola M, Grimes HL, Fontanillo C, Komurov K, MacBeth K, Starczynowski DT. A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes. Nature Medicine, 2016 Jul;22(7):724-34. PMID: 27294874
  4. Fang J, Barker B, Bolanos L, Liu X, Jerez A, Makishima H, Christie S, Chen X, Rao DS, Grimes HL, Komurov K, Weirauch MT, Cancelas JA, Maciejewski JP, Starczynowski DT. Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-kB gene network. (2014). Cell Reports, 2014 8: 1328-38. PMID: 25199827
  5. Fang J, Rhyasen G, Bolanos L, Rasch C, Varney M, Wunderlich M, Goyama S, Jansen G, Cloos J, Rigolino C, Cortelezzi A, Mulloy JC, Oliva EN, Cuzzola M, Starczynowski DT. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. (2012). Blood, 120(4): 858-67. PMID: 22685174
  6. Dev A*, Fang J*, Sathyanarayana P, Pradeep A, Emerson C, Wojchowski DM. During EPO or anemia challenge, erythroid progenitor cells transit through a selectively expandable proerythroblast pool. (2010). Blood, 116: 5334-46. (*co-first author). PMID: 20810925
  7. Fang J, Menon M, Zhang D, Torbett B, Oxburgh L, Tschan M, Houde E, Wojchowski DM. Attenuation of EPO-dependent erythroblast formation by death-associated protein kinase-2. (2008). Blood, 112: 886-90. PMID: 18535204
  8. Fang J, Menon M, Kapelle W, Bogacheva O, Bogachev O, Houde E, Browne S, Sathyanarayana P, Wojchowski DM. EPO modulation of cell-cycle regulatory genes, and cell division, in primary bone marrow erythroblasts. (2007). Blood, 110: 2361-70. PMID: 17548578
  9. Shen ZX*, Shi ZZ*, Fang J*, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De Thé H, Wang ZY, Chen SJ, Chen Z. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. (2004). Proc Natl Acad Sci U S A, 101: 5328-35. (*co-first author). PMID: 15044693

 

Complete List of Published Work:
https://www.ncbi.nlm.nih.gov/sites/myncbi/1xkZeb34v5dAn/collections/54514359/public/